BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghany MG, Morgan TR;  AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71:686-721. [PMID: 31816111 DOI: 10.1002/hep.31060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 72.5] [Reference Citation Analysis]
Number Citing Articles
1 Talebi A, Kargar M. Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major. Int J Clin Pract 2021;75:e14951. [PMID: 34965654 DOI: 10.1111/ijcp.14951] [Reference Citation Analysis]
2 Yeo YH, Gao X, Wang J, Li Q, Su X, Geng Y, Huang R, Wu C, Ji F, Sundaram V, Noureddin M, Buti M, Ayoub WS. The impact of COVID-19 on the cascade of care of HCV in the US and China. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100685] [Reference Citation Analysis]
3 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Talal AH, Ding YX, Markatou M. Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users. World J Hepatol 2022; 14(5): 972-983 [DOI: 10.4254/wjh.v14.i5.972] [Reference Citation Analysis]
5 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830 [PMID: 34447228 DOI: 10.3748/wjg.v27.i29.4818] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gómez-Ayerbe C, Palacios R, Ríos MJ, Téllez F, Sayago C, Martín-Aspas A, Camacho A, Muñoz L, Santos J; HEPAVIR Group. Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic? Int J STD AIDS 2021;:9564624211033756. [PMID: 34293985 DOI: 10.1177/09564624211033756] [Reference Citation Analysis]
7 Wong YJ, Thurairajah PH, Kumar R, Tan J, Fock KM, Law NM, Li W, Kwek A, Tan YB, Koh J, Lee ZC, Kumar LS, Teo EK, Ang TL. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. J Gastroenterol Hepatol. 2020;. [PMID: 33217040 DOI: 10.1111/jgh.15324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Jiang X, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. Antiviral Res 2020;181:104871. [PMID: 32717286 DOI: 10.1016/j.antiviral.2020.104871] [Reference Citation Analysis]
9 Colombatto P, Palmisano E, Ricco G, Cavallone D, Oliveri F, Coco B, Salvati A, Romagnoli V, Surace L, Vatteroni M, Pistello M, Virdis A, Bonino F, Brunetto MR. Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. JCM 2022;11:1406. [DOI: 10.3390/jcm11051406] [Reference Citation Analysis]
10 Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res 2021;51:517-27. [PMID: 33507588 DOI: 10.1111/hepr.13623] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, Shen J, Shang N, Han J, Wang H, Kang W, Meng F. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol 2021;21:395. [PMID: 34686147 DOI: 10.1186/s12876-021-01974-4] [Reference Citation Analysis]
12 Sohn W. Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma. Korean J Intern Med 2021;36:286-7. [PMID: 33725434 DOI: 10.3904/kjim.2021.078] [Reference Citation Analysis]
13 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [PMID: 34904036 DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
14 Akimov IA, Timofeev DI, Mavzyutov AR, Ivanov MK. Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR. Klin Lab Diagn 2021;66:122-8. [PMID: 33734647 DOI: 10.51620/0869-2084-2021-66-2-122-128] [Reference Citation Analysis]
15 Devarapalli UV, Sarma MS, Mathiyazhagan G. Gut and liver involvement in pediatric hematolymphoid malignancies. World J Gastrointest Oncol 2022; 14(3): 587-606 [DOI: 10.4251/wjgo.v14.i3.587] [Reference Citation Analysis]
16 Siddique SM, May FP. Race-Based Clinical Recommendations in Gastroenterology. Gastroenterology 2021:S0016-5085(21)04050-6. [PMID: 34890599 DOI: 10.1053/j.gastro.2021.12.234] [Reference Citation Analysis]
17 Chan PL, Le LV, Ishikawa N, Easterbrook P. Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020. Glob Health Med 2021;3:253-61. [PMID: 34782866 DOI: 10.35772/ghm.2021.01065] [Reference Citation Analysis]
18 Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, Ali A, Schiffer CA. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chem Rev 2021;121:3238-70. [PMID: 33410674 DOI: 10.1021/acs.chemrev.0c00648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
19 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. mBio 2020;11:e00172-20. [PMID: 32234812 DOI: 10.1128/mBio.00172-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ahrens KA, Rossen LM, Burgess AR, Palmsten KK, Ziller EC. Rural-Urban Residence and Maternal Hepatitis C Infection, U.S.: 2010-2018. Am J Prev Med 2021;60:820-30. [PMID: 33640230 DOI: 10.1016/j.amepre.2020.12.020] [Reference Citation Analysis]
22 Abu-Freha N, Mathew Jacob B, Elhoashla A, Afawi Z, Abu-Hammad T, Elsana F, Paz S, Etzion O. Chronic hepatitis C: Diagnosis and treatment made easy. Eur J Gen Pract 2022;28:102-8. [PMID: 35579223 DOI: 10.1080/13814788.2022.2056161] [Reference Citation Analysis]
23 Cabezas J, Llerena S, Mateo M, Álvarez R, Cobo C, González V, Martró E, Cuadrado A, Crespo J. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel) 2021;11:877. [PMID: 34068955 DOI: 10.3390/diagnostics11050877] [Reference Citation Analysis]
24 Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Reference Citation Analysis]
25 Wong YJ, Thurairajah PH, Kumar R, Fock KM, Law NM, Chong SY, Manejero FG, Ang TL, Teo EK, Tan J. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. Clin Mol Hepatol 2021;27:474-85. [PMID: 33601868 DOI: 10.3350/cmh.2021.0015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Reference Citation Analysis]
27 Masaki N, Kawasaki Y, Nozaki Y, Yanase M. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct-acting antivirals in Japan: Evidence based on the nationwide, real-world database in Japan. Hepatol Res 2021;51:417-25. [PMID: 33217105 DOI: 10.1111/hepr.13596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
29 Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. Front Immunol 2022;13:882064. [DOI: 10.3389/fimmu.2022.882064] [Reference Citation Analysis]
30 Matsui T, Hayashi S, Tanaka Y. Is it necessary to revise the liver transplantation guidelines to meet the current situation? Hepatol Res 2021;51:1177-8. [PMID: 34850498 DOI: 10.1111/hepr.13710] [Reference Citation Analysis]
31 Enomoto M, Vutien P, Kawada N. Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance? Hepatol Commun 2022;6:445-7. [PMID: 35202513 DOI: 10.1002/hep4.1864] [Reference Citation Analysis]
32 Squires JE, Balistreri WF. Treatment of Hepatitis C: A New Paradigm toward Viral Eradication. The Journal of Pediatrics 2020;221:12-22.e1. [DOI: 10.1016/j.jpeds.2020.02.082] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Hecker C, Welponer T, Herold M, Trinka E, Broussalis E, Killer-Oberpfalzer M. Update on treatment strategies for vasculitis affecting the central nervous system. Drug Discov Today 2021:S1359-6446(21)00501-8. [PMID: 34838730 DOI: 10.1016/j.drudis.2021.11.020] [Reference Citation Analysis]
34 Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020;31:2678-87. [PMID: 32843477 DOI: 10.1681/ASN.2020050686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
35 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Reference Citation Analysis]
36 Minami T, Tateishi R, Fujiwara N, Nakagomi R, Nakatsuka T, Sato M, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Hanajiri K, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Ohki T, Arai M, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Koike Y, Akamatsu M, Mitsui H, Fujie H, Ogura K, Yoshida H, Wada T, Kurai K, Maekawa H, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Moriya K, Yotsuyanagi H, Koike K. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. Liver Cancer 2021;10:309-19. [PMID: 34414119 DOI: 10.1159/000513705] [Reference Citation Analysis]
37 Villegas-galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis c-viremic donors: a systematic review with meta-analysis. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.01.010] [Reference Citation Analysis]
38 Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol 2020;6:163-9. [PMID: 33145422 DOI: 10.5114/ceh.2020.98606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Varotti G, Dodi F, Paoletti E, Bruno A, Fontana I. Successful Antiviral Treatment with Direct-Acting Antivirals for Hepatitis C Virus Infection during Peritransplant Period in a Kidney Transplant Recipient. Case Rep Transplant 2021;2021:1948560. [PMID: 34931152 DOI: 10.1155/2021/1948560] [Reference Citation Analysis]
40 Ridruejo E, Piñero F, Mendizabal M, Silva M; Latin American Liver Research Educational, Awareness Network (LALREAN). Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. J Viral Hepat 2021;28:446-7. [PMID: 33147362 DOI: 10.1111/jvh.13433] [Reference Citation Analysis]
41 Jiang X, Chang L, Yan Y, Ji H, Sun H, Guo F, Wang L. A study based on four immunoassays: Hepatitis C virus antibody against different antigens may have unequal contributions to detection. Virol J 2021;18:137. [PMID: 34217305 DOI: 10.1186/s12985-021-01608-x] [Reference Citation Analysis]
42 Patel S, Martin MT, Flamm SL. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int 2021;41:3024-7. [PMID: 34592051 DOI: 10.1111/liv.15075] [Reference Citation Analysis]
43 Lin SH, Wu KT, Wang CC, Huang KT, Chen KD, Lin CC, Hsu LW, Chiu KW. HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation. J Int Med Res 2021;49:3000605211034945. [PMID: 34344219 DOI: 10.1177/03000605211034945] [Reference Citation Analysis]
44 Durand M, Nagot N, Nhu QBT, Vallo R, Thuy LLT, Duong HT, Thanh BN, Rapoud D, Quillet C, Tran HT, Michel L, Tuyet TNT, Hai OKT, Hai VV, Feelemyer J, Perre PV, Jarlais DD, Minh KP, Laureillard D, Molès JP. Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs. J Clin Med 2021;10:4824. [PMID: 34768343 DOI: 10.3390/jcm10214824] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Haque LY, Fiellin DA. Bridging the Gap: Dual Fellowship Training in Addiction Medicine and Digestive Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-022-07478-9] [Reference Citation Analysis]
46 Dormanesh A, Wang JH, Mishori R, Cupertino P, Longcoy J, Kassaye S, Kaljee L, Smith C, Loffredo CA. Adherence to clinical follow-up recommendations for liver function tests: A cross-sectional study of patients with HCV and their associated risk behaviors. Prev Med Rep 2021;23:101482. [PMID: 34307001 DOI: 10.1016/j.pmedr.2021.101482] [Reference Citation Analysis]
47 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Kowalik-Mikołajewska B, Marczyńska M. Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klin Padiatr 2020. [PMID: 33339066 DOI: 10.1055/a-1304-3542] [Reference Citation Analysis]
49 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Jose R, Kahal D, Testa K, Goldstein ND; MBI4. A Qualitative Study of Implementing Universal Hepatitis C Screening Among Adults at an Urban Community-Based Health Provider in Delaware. Dela J Public Health 2021;7:16-23. [PMID: 34467206 DOI: 10.32481/djph.2021.07.006] [Reference Citation Analysis]
51 Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J 2021;9:1101-2. [PMID: 34687156 DOI: 10.1002/ueg2.12167] [Reference Citation Analysis]
52 Boyarsky BJ, Strauss AT, Segev DL. Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier. World J Surg 2021. [PMID: 33471156 DOI: 10.1007/s00268-020-05924-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Sakamori R, Yamada R, Shinkai K, Doi A, Tahata Y, Shigekawa M, Kodama T, Hikita H, Yamada T, Tatsumi T, Takehara T. Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis. Intern Med 2021;60:745-50. [PMID: 33642562 DOI: 10.2169/internalmedicine.6029-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Higley C, Hsu CC, Smith C, Nadella S, Lalos AT. Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports. World J Hepatol 2020; 12(12): 1341-1348 [PMID: 33442459 DOI: 10.4254/wjh.v12.i12.1341] [Reference Citation Analysis]
56 Rupasinghe D, Choi JY, Kumarasamy N, Pujari S, Sun LP, Merati TP, Lee MP, Kinh NV, Kiertiburanakul S, Do CD, Avihingsanon A, Ross J, Jiamsakul A; o n behalf of IeDEA Asia-Pacific. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med 2022. [PMID: 35218151 DOI: 10.1111/hiv.13280] [Reference Citation Analysis]
57 Cotter TG, Wang J, Lieber SR, Odenwald MA, Rich NE, Marrero JA, Singal AG, Mitchell MC, Aronsohn A, Charlton M, Fung J. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplant Direct 2021;7:e707. [PMID: 34124343 DOI: 10.1097/TXD.0000000000001154] [Reference Citation Analysis]
58 Spradling PR, Zhong Y, Moorman AC, Rupp LB, Lu M, Gordon SC, Teshale EH, Schmidt MA, Daida YG, Boscarino JA; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatol Commun 2021;5:400-11. [PMID: 33681675 DOI: 10.1002/hep4.1632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Nasir M, Vinsard DG, Wakefield D, Karagozian R. The important role of immunization in alcoholic and non-alcoholic chronic liver disease: A population-based study. J Dig Dis 2020;21:583-92. [PMID: 32729256 DOI: 10.1111/1751-2980.12926] [Reference Citation Analysis]
60 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Mkuu RS, Shenkman EA, Muller KE, Huo T, Salloum RG, Cabrera R, Zarrinpar A, Thomas E, Szurek SM, Nelson DR. Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data. Medicine 2021;100:e28316. [DOI: 10.1097/md.0000000000028316] [Reference Citation Analysis]
62 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
63 Shanmuganathan M, Sarfaraz MO, Kroezen Z, Philbrick H, Poon R, Don-Wauchope A, Puglia M, Wishart D, Britz-McKibbin P. A Cross-Platform Metabolomics Comparison Identifies Serum Metabolite Signatures of Liver Fibrosis Progression in Chronic Hepatitis C Patients. Front Mol Biosci 2021;8:676349. [PMID: 34414211 DOI: 10.3389/fmolb.2021.676349] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Lin CY, Chien RN, Sheen IS. The 2020 Nobel Prize in Medicine for the Discovery of Hepatitis C Virus: An epic saga of the fight against a troublesome virus. Biomed J 2021:S2319-4170(21)00088-3. [PMID: 34245922 DOI: 10.1016/j.bj.2021.07.001] [Reference Citation Analysis]
65 Solomon SS, Wagner-cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00397-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells 2021;10:2759. [PMID: 34685739 DOI: 10.3390/cells10102759] [Reference Citation Analysis]
67 Deng H, Guo F, Yu W, Li L, Xia Y, Guan Y, Li J. Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients. Virus Res 2021;302:198453. [PMID: 33991622 DOI: 10.1016/j.virusres.2021.198453] [Reference Citation Analysis]
68 Ivantes CAP, Silva BCD, Acosta GG, Tawil FBNE, Nisihara R. NON-ADHERENCE TO HEPATITIS C TREATMENT: A BRAZILIAN REPORT. Arq Gastroenterol 2021;58:456-60. [PMID: 34909850 DOI: 10.1590/S0004-2803.202100000-83] [Reference Citation Analysis]
69 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Reference Citation Analysis]
70 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
71 Ahumada A, Rayón L, Usón C, Bañares R, Alonso Lopez S. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? World J Gastroenterol 2021; 27(40): 6737-6749 [PMID: 34790004 DOI: 10.3748/wjg.v27.i40.6737] [Reference Citation Analysis]
72 Merchante N, Mena Á, Pascasio JM, Marco A, Rodriguez M, Hernandez-Guerra M, Simón MA. Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection. Medicine (Baltimore) 2021;100:e27838. [PMID: 34797315 DOI: 10.1097/MD.0000000000027838] [Reference Citation Analysis]
73 Zhou Y, Xie W, Zheng C, Liu L, Chen Z, Wang X. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Clin Endocrinol (Oxf) 2021. [PMID: 34913180 DOI: 10.1111/cen.14660] [Reference Citation Analysis]
74 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
75 Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM, Townley C, Mahomed F, Foster GR. English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment Pharmacol Ther 2020;52:168-81. [PMID: 32441382 DOI: 10.1111/apt.15780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Reference Citation Analysis]
77 Gibbs D, Grebely J, Sutherland R, Larney S, Butler K, Dietze PM, Starr M, Peacock A. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. Drug Alcohol Rev 2021. [PMID: 33759276 DOI: 10.1111/dar.13282] [Reference Citation Analysis]
78 Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. Int J Drug Policy 2021;101:103570. [PMID: 34954493 DOI: 10.1016/j.drugpo.2021.103570] [Reference Citation Analysis]
79 Vallejo A, Moldes LM, Trigo M, Ordoñez P, Rodriguez-Otero L, Cabrera JJ, Gude MJ, Navarro D, Cañizares A, García-Campello M, Agulla A, Aguilera A; en nombre del Grupo de Estudio del DUSP en Galicia. Generalized implementation of reflex testing of hepatitis C in Galicia: Results for reflection. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00025-2. [PMID: 33632540 DOI: 10.1016/j.eimc.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kim TH, Lee SW. Aptamers for Anti-Viral Therapeutics and Diagnostics. Int J Mol Sci 2021;22:4168. [PMID: 33920628 DOI: 10.3390/ijms22084168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Reference Citation Analysis]
82 Li YR, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. World J Gastroenterol 2021; 27(31): 5181-5188 [PMID: 34497443 DOI: 10.3748/wjg.v27.i31.5181] [Reference Citation Analysis]
83 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
84 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
85 Pearce ME, Yu A, Alvarez M, Bartlett SR, Binka M, Jeong D, Clementi E, Adu P, Wilton J, Yoshida EM, Pick N, Buxton JA, Wong J, Jassem A, Krajden M, Janjua NZ. Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019. PLoS One 2020;15:e0244575. [PMID: 33382774 DOI: 10.1371/journal.pone.0244575] [Reference Citation Analysis]
86 Kang SH, Kim MY. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care. Clin Mol Hepatol 2021;27:100-2. [PMID: 33317234 DOI: 10.3350/cmh.2020.0312] [Reference Citation Analysis]
87 Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Reference Citation Analysis]
88 Talal AH, Markatou M, Sofikitou EM, Brown LS, Perumalswami P, Dinani A, Tobin JN. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). Contemp Clin Trials 2022;112:106632. [PMID: 34813962 DOI: 10.1016/j.cct.2021.106632] [Reference Citation Analysis]
89 Bradshaw D, Bibby DF, Manso CF, Piorkowska R, Mohamed H, Ledesma J, Bubba L, Chan YT, Ngui SL, Carne S, Mbisa JL; STOP-HCV Consortium. Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. Clin Microbiol Infect 2021:S1198-743X(21)00373-6. [PMID: 34245902 DOI: 10.1016/j.cmi.2021.06.042] [Reference Citation Analysis]
90 Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
91 Greenaway E, Haines A, Ling SC, Krahn M. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood. J Pediatr. 2020;. [PMID: 32890583 DOI: 10.1016/j.jpeds.2020.08.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
92 Woolley AE, Singh SK. The curious phenomenon of early cardiac allograft rejection with hepatitis C‒infected donor heart transplants. J Heart Lung Transplant 2020;39:1208-9. [PMID: 32978057 DOI: 10.1016/j.healun.2020.09.002] [Reference Citation Analysis]
93 Li BY, Tan W, Zou JL, He Y, Yoshida S, Jiang B, Zhou YD. Role of interferons in diabetic retinopathy. World J Diabetes 2021; 12(7): 939-953 [PMID: 34326947 DOI: 10.4239/wjd.v12.i7.939] [Reference Citation Analysis]
94 Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. Glob Health Med 2021;3:276-82. [PMID: 34782869 DOI: 10.35772/ghm.2021.01075] [Reference Citation Analysis]
95 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
96 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Tripathi K, Loganathan S, Trivedi N, Abraham GM. Impact of hepatitis C remission on glycemic control in patients with type 2 diabetes mellitus: primary care outpatient experience. J Community Hosp Intern Med Perspect 2021;11:354-6. [PMID: 34234905 DOI: 10.1080/20009666.2021.1886631] [Reference Citation Analysis]
98 Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. 2021;74:458-465. [PMID: 33303216 DOI: 10.1016/j.jhep.2020.10.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
99 Cotter TG, Aronsohn A, Reddy KG, Charlton M. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation 2021;105:1285-90. [DOI: 10.1097/tp.0000000000003382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
100 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
102 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
103 Mikulska M, Knelange N, Nicolini LA, Tridello G, Santarone S, Di Bartolomeo P, de la Camara R, Cuéllar C, Velardi A, Perruccio K, Ljungman P, Zaucha J, Piekarska A, Basak G, Karakulska-Prystupiuk E, Angelucci E, Ciceri F, Lupo-Stanghellini MT, Fouillard L, García-Cadenas I, Menconi M, Blau IW, Nassi L, Cesaro S, Styczynski J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. J Infect 2021:S0163-4453(21)00539-9. [PMID: 34757138 DOI: 10.1016/j.jinf.2021.10.024] [Reference Citation Analysis]
104 Coppock D, Chou E, Gracely E, Gross R, Heun-Lee D. Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics. PLoS One 2020;15:e0235778. [PMID: 32645083 DOI: 10.1371/journal.pone.0235778] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
106 Abd El-Wahab EW, Metwally M, Lotfy N. Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: significance of isolated hepatitis B core antibodies. Trop Med Int Health 2021;26:882-94. [PMID: 33860608 DOI: 10.1111/tmi.13588] [Reference Citation Analysis]
107 Osuch S, Laskus T, Berak H, Perlejewski K, Metzner KJ, Paciorek M, Radkowski M, Caraballo Cortés K. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. Sci Rep 2020;10:16060. [PMID: 32994477 DOI: 10.1038/s41598-020-73137-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
108 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Silva JPCG, Jesus LS, Isabel Schinoni M, Oliveira IS, Atta MLBS, Atta AM. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment. Int Immunopharmacol 2021;93:107405. [PMID: 33529909 DOI: 10.1016/j.intimp.2021.107405] [Reference Citation Analysis]
110 Fuster D, García-Calvo X, Zuluaga P, Bolao F, Muga R. Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World J Gastroenterol 2021; 27(23): 3223-3237 [PMID: 34163107 DOI: 10.3748/wjg.v27.i23.3223] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Yamana Y, Kanda T, Matsumoto N, Honda M, Kumagawa M, Sasaki R, Kanezawa S, Mizutani T, Yamagami H, Masuzaki R, Ishii T, Nirei K, Moriyama M. Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. J Clin Med 2021;10:5529. [PMID: 34884231 DOI: 10.3390/jcm10235529] [Reference Citation Analysis]
112 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Reference Citation Analysis]
113 Kienes I, Weidl T, Mirza N, Chamaillard M, Kufer TA. Role of NLRs in the Regulation of Type I Interferon Signaling, Host Defense and Tolerance to Inflammation. Int J Mol Sci 2021;22:1301. [PMID: 33525590 DOI: 10.3390/ijms22031301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
114 Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2021:gutjnl-2020-323663. [PMID: 33741640 DOI: 10.1136/gutjnl-2020-323663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
115 Setiawan VW, Rosen HR. Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis. Hepatology 2020;72:1897-9. [PMID: 33205438 DOI: 10.1002/hep.31639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Oztürk S, Ağalar C. Updating the Signal-to-cutoff Level to Reduce Anti-hepatitis C Virus False Positivity. Jundishapur J Microbiol 2021;14. [DOI: 10.5812/jjm.119110] [Reference Citation Analysis]
117 Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis 2020;222:1334-44. [PMID: 32406487 DOI: 10.1093/infdis/jiaa254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Raasikh T, Jamali T, Flores A, Cotton RT, Ramanathan V, Tan HP, Hernaez R. Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation. Aliment Pharmacol Ther 2021;54:571-82. [PMID: 34265111 DOI: 10.1111/apt.16508] [Reference Citation Analysis]
119 Pruß A, Chandrasekar A, Sánchez-Ibáñez J, Lucas-Samuel S, Kalus U, Rabenau HF. Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus. Transfus Med Hemother 2021;48:12-22. [PMID: 33708048 DOI: 10.1159/000513179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Falade-Nwulia O, Sulkowski MS. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. J Infect Dis 2020;222:S745-57. [PMID: 33245350 DOI: 10.1093/infdis/jiaa534] [Reference Citation Analysis]
121 AbdAllah M, Alboraie M, Abdel-Razek W, Hassany M, Ammar I, Kamal E, Alalfy M, Okasha A, El Akel W, Shaaban E, Elbaz T, Hefny Z, Gomaa A, El-Bendary M, El-Serafy M, Esmat G, Doss W, El-Sayed MH. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver Int 2021;41:1494-7. [PMID: 33905164 DOI: 10.1111/liv.14913] [Reference Citation Analysis]
122 Tokushima Y, Tago M, Tokushima M, Katsuki NE, Iwane S, Eguchi Y, Yamashita SI. Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. Int J Gen Med 2020;13:743-50. [PMID: 33061544 DOI: 10.2147/IJGM.S268857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Ortonne V, Wlassow M, Hézode C, François M, Rosa I, Pawlotsky JM, Chevaliez S. Diagnosis and monitoring of hepatitis C virus infection using the cobas® HCV test for use on the cobas® 4800 system. J Clin Virol 2021;141:104873. [PMID: 34111663 DOI: 10.1016/j.jcv.2021.104873] [Reference Citation Analysis]
124 Rochlani Y, Diab K, Jorde UP. Hepatitis C-Positive Donors in Cardiac Transplantation: Problems and Opportunities. Curr Heart Fail Rep 2020;17:106-15. [PMID: 32474734 DOI: 10.1007/s11897-020-00466-y] [Reference Citation Analysis]
125 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
126 Pluta M, Pokorska-Śpiewak M, Aniszewska M, Lewandowski Z, Kowalik-Mikołajewska B, Marczyńska M. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals. Minerva Pediatr (Torino) 2022;74:23-30. [PMID: 33438851 DOI: 10.23736/S2724-5276.20.05881-8] [Reference Citation Analysis]
127 Noviana E, Ozer T, Carrell CS, Link JS, Mcmahon C, Jang I, Henry CS. Microfluidic Paper-Based Analytical Devices: From Design to Applications. Chem Rev 2021;121:11835-85. [DOI: 10.1021/acs.chemrev.0c01335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
128 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
129 Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel) 2021;11:2236. [PMID: 34943471 DOI: 10.3390/diagnostics11122236] [Reference Citation Analysis]
130 Ahmed HR, Waly NGFM, Abd El-Baky RM, Yahia R, Hetta HF, Elsayed AM, Ibrahem RA. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One 2021;16:e0249770. [PMID: 33857212 DOI: 10.1371/journal.pone.0249770] [Reference Citation Analysis]
131 Talal AH, Ding Y, Markatou M. Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users. WJH 2022;14:973-84. [DOI: 10.4254/wjh.v14.i5.973] [Reference Citation Analysis]
132 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
133 Jothimani D, Danielraj S, Narasimhan G, Kaliamoorthy I, Rajakumar A, Palaniappan K, Palanichamy S, Rammohan A, Ramachandran H, Rajalingam R, Rela M. Nonalcoholic Steatohepatitis: A Rapidly Increasing Indication for Liver Transplantation in India. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 D'Ambrosio R, Ioannou GN. Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatol Commun 2021;5:1465-8. [PMID: 34510832 DOI: 10.1002/hep4.1733] [Reference Citation Analysis]
135 Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, Mutimer D, Ghalib R, Crown E, Lovell SS, Hu Y, Moreno C, Nelson DR, Colombo M, Papatheodoridis G, Rockstroh JK, Skoien R, Lawitz E, Jacobson IM. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. Am J Gastroenterol 2021;116:1896-904. [PMID: 34465693 DOI: 10.14309/ajg.0000000000001332] [Reference Citation Analysis]
136 Homkrailas P, Ayoub WS, Martin P, Bunnapradist S. Kidney utilization and outcomes of liver transplant recipients who were listed for kidney after liver transplant after the implementation of safety net policy. Clin Transplant 2021;:e14522. [PMID: 34716954 DOI: 10.1111/ctr.14522] [Reference Citation Analysis]
137 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Reference Citation Analysis]
138 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
139 Clemente MG, Antonucci R, Sotgiu G, Dettori M, Piana A, Vajro P. Present and future management of viral hepatitis B and C in children. Clinics and Research in Hepatology and Gastroenterology 2020;44:801-9. [DOI: 10.1016/j.clinre.2020.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Sun C, Chiu W, Chen P, Chang H, Guu T, Shityakov S, Miller AH, Felger JC, Chang JP, Su K. Depression-free after Interferon-α exposure indicates less incidence of depressive disorder: A longitudinal study in Taiwan. Brain, Behavior, and Immunity 2020;88:125-31. [DOI: 10.1016/j.bbi.2020.05.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
141 Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther 2021. [PMID: 34812502 DOI: 10.1111/apt.16691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Lok AS. Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C? Clin Infect Dis 2021;72:787-8. [PMID: 32052046 DOI: 10.1093/cid/ciaa147] [Reference Citation Analysis]
143 Erken E, Altunoren O, Gungor O. Poor management of hepatitis C infection will cause serious issues for patients with advanced chronic kidney disease. J Evid Based Med 2021;14:87-9. [PMID: 33988914 DOI: 10.1111/jebm.12433] [Reference Citation Analysis]
144 Lin CP, Liang PC, Huang CI, Yeh ML, Hsu PY, Hsu CT, Wei YJ, Liu TW, Hsieh MY, Hou NJ, Jang TY, Lin YH, Wang CW, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. PLoS One 2021;16:e0245479. [PMID: 33539408 DOI: 10.1371/journal.pone.0245479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Romano C, Esposito S, Ferrara R, Cuomo G. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther 2021;21:661-74. [PMID: 33147106 DOI: 10.1080/14712598.2021.1847268] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Pham LV, Pedersen MS, Fahnøe U, Fernandez-Antunez C, Humes D, Schønning K, Ramirez S, Bukh J. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4. Gut 2021:gutjnl-2020-323585. [PMID: 33833066 DOI: 10.1136/gutjnl-2020-323585] [Reference Citation Analysis]
147 Patel D, Teckman J. Liver disease with unknown etiology - have you ruled out alpha-1 antitrypsin deficiency? Ther Adv Chronic Dis 2021;12_suppl:2040622321995684. [PMID: 34408828 DOI: 10.1177/2040622321995684] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
148 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
149 Shiha G, Mikhail NNH, Soliman R, Hassan A, Eslam M. Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study. Hepatol Int 2022. [PMID: 35034266 DOI: 10.1007/s12072-021-10284-6] [Reference Citation Analysis]
150 Cachay ER, Mena A, Morano L, Benitez L, Maida I, Mendoza C, Hill L, Torriani F, Soriano V, Mathews WC; HCV-HIV Transatlantic Research Network (HCV-TREN). Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach. J Int Assoc Provid AIDS Care 2021;20:23259582211024771. [PMID: 34132142 DOI: 10.1177/23259582211024771] [Reference Citation Analysis]
151 Shapiro CBH, Cheung RC, Giori NJ. Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update. J Arthroplasty 2021;36:467-70. [PMID: 32900563 DOI: 10.1016/j.arth.2020.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
153 Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshioka K, Tanaka J, Muramatsu M, Wakita T, Aizaki H. Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers. Hepatol Int 2021. [PMID: 34855104 DOI: 10.1007/s12072-021-10269-5] [Reference Citation Analysis]
154 Pinto RB, Ramos ARL, Padua LT, Swayze EJ, Cambou MC, Fiorini M, Melo M, Santos BR, Canti ICT, Silveira MLR, Solari MIG, de Correa JF, Chew K, Dos Santos Varella IR, Nielsen-Saines K. Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program. Int J Infect Dis 2021;110:62-8. [PMID: 34273517 DOI: 10.1016/j.ijid.2021.07.019] [Reference Citation Analysis]
155 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
156 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
157 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
158 Li W, Liang J, An J, Liu L, Hou Y, Li L, Zhao W, Cui L, Xue N, Al-dhamin Z, Han T, Nan Y, Zhang L, Granito A. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7395506] [Reference Citation Analysis]
159 Kim NG, Kullar R, Khalil H, Saab S. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. J Viral Hepat. 2020;27:762-769. [PMID: 32386099 DOI: 10.1111/jvh.13317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
160 Laiwatthanapaisan R, Sirinawasatien A. Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults. World J Clin Cases 2021; 9(18): 4491-4499 [PMID: 34222417 DOI: 10.12998/wjcc.v9.i18.4491] [Reference Citation Analysis]
161 Messina V, Russo A, Parente E, Russo G, Raimondo T, Salzillo A, Simeone F, Onorato L, Di Caprio G, Pisaturo M, Coppola N. Innovative procedures for micro-elimination of HCV infection in persons who use drugs. J Viral Hepat 2020;27:1437-43. [PMID: 32810330 DOI: 10.1111/jvh.13375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
162 Chaillon A, Rand EB, Reau N, Martin NK. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis 2019;69:1888-95. [PMID: 30689769 DOI: 10.1093/cid/ciz063] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
163 Paul Noel B, Peter C, Emma R, Asthika A, Francis DJ. Cohort study: Apparent redundancy of fibrosis assessment in young persons with HCV; development of realistic approaches to break the paradigm. Ann Hepatol 2021;27:100550. [PMID: 34606981 DOI: 10.1016/j.aohep.2021.100550] [Reference Citation Analysis]
164 Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver Int 2021. [PMID: 34154034 DOI: 10.1111/liv.14991] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Mei YY, Chen YM, Wu YK, Zhang XH, Xu WX. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Can J Gastroenterol Hepatol 2020;2020:8872120. [PMID: 33194875 DOI: 10.1155/2020/8872120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Ampuero J, Carmona I, Sousa F, Rosales JM, Lopez-Garrido A, Casado M, Figueruela B, Aparicio A, Andrade R, Guerra-Veloz MF, Maraver M, Pascasio JM, Estevez M, Romero-Gomez M. A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. Am J Gastroenterol 2021. [PMID: 34817975 DOI: 10.14309/ajg.0000000000001503] [Reference Citation Analysis]
167 Hagymási K. The Nobel Prize in Physiology or Medicine-2020. Struct Chem 2021;:1-5. [PMID: 33584076 DOI: 10.1007/s11224-021-01731-z] [Reference Citation Analysis]
168 Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, Krajden M, George J, Matthews GV, Hajarizadeh B, Degenhardt L, Grebely J, Dore GJ. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. J Hepatol 2021;74:293-302. [PMID: 32931879 DOI: 10.1016/j.jhep.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
169 Mukherjee S, Colby D, Ramautarsing R, Popping S, Sriplienchan S, Chinbunchorn T, Phanuphak N, van de Vijver D. Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study. J Virus Erad 2021;7:100042. [PMID: 34141441 DOI: 10.1016/j.jve.2021.100042] [Reference Citation Analysis]
170 Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious Complications of Injection Drug Use. Med Clin North Am 2022;106:187-200. [PMID: 34823730 DOI: 10.1016/j.mcna.2021.08.006] [Reference Citation Analysis]
171 Czarnecka P, Czarnecka K, Tronina O, Baczkowska T, Durlik M. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? Ren Fail 2022;44:434-49. [PMID: 35260039 DOI: 10.1080/0886022X.2022.2047069] [Reference Citation Analysis]
172 Sawinski D, Wong T, Goral S. Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. Clin Transplant 2020;34:e14048. [PMID: 32700341 DOI: 10.1111/ctr.14048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int 2020;40:1545-55. [PMID: 32078234 DOI: 10.1111/liv.14408] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
174 Chen Y, Chang T, Chen C, Cheng P, Lo C, Mo L, Chen C, Huang C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Huang J, Yang C, Hu J, Lin C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Dai C, Kao J, Chuang W, Lin H, Chen C, Tseng K, Yu M; on behalf of TACR investigators. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses 2022;14:333. [DOI: 10.3390/v14020333] [Reference Citation Analysis]
175 De A, Roy A, Verma N, Mishra S, Premkumar M, Taneja S, Singh V, Duseja A. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton) 2021. [PMID: 34453374 DOI: 10.1111/nep.13968] [Reference Citation Analysis]
176 Elkassem AA, Allen BC, Lirette ST, Cox KL, Remer EM, Pickhardt PJ, Lubner MG, Sirlin CB, Dondlinger T, Schmainda M, Jacobus RB, Severino PE, Smith AD. Multiinstitutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients with Hepatitis C. AJR Am J Roentgenol 2021. [PMID: 34935403 DOI: 10.2214/AJR.21.27062] [Reference Citation Analysis]
177 Ng YZ, Lai LL, Wong SW, Mohamad SY, Chuah KH, Chan WK. Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease. PLoS One 2021;16:e0250300. [PMID: 33939744 DOI: 10.1371/journal.pone.0250300] [Reference Citation Analysis]
178 Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, Afshar Y, Terrault NA. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:318-65. [PMID: 32946672 DOI: 10.1002/hep.31559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
179 Cacciola I, Pitrone C, Franzè MS, Mazzeo C, Muscianisi M, Porcari S, Pintabona G, Morace C, Basile G, Cucinotta E, Pollicino T, Raimondo G. Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. Ann Hepatol 2021;:100578. [PMID: 34752948 DOI: 10.1016/j.aohep.2021.100578] [Reference Citation Analysis]
180 Arora U, Garg P, Agarwal S, Nischal N, Shalimar, Wig N. Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis. Lancet Infect Dis 2021;21:e399-406. [PMID: 34023004 DOI: 10.1016/S1473-3099(20)30765-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Piedade J, Pereira G, Guimarães L, Duarte J, Victor L, Baldin C, Inacio C, Santos R, Chaves Ú, Nunes EP, Grinsztejn B, Veloso VG, Fernandes F, Perazzo H. Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes. Sci Rep 2021;11:11681. [PMID: 34083617 DOI: 10.1038/s41598-021-91099-1] [Reference Citation Analysis]
183 Yen H, Chen Y, Lai J, Chen H, Yao C, Huang S, Liu I, Zeng Y, Yang F, Siao F, Chen M, Su P. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. JCM 2022;11:1853. [DOI: 10.3390/jcm11071853] [Reference Citation Analysis]
184 Dai CY, Chuang WL, Yu ML. EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues. J Hepatol 2021;74:473-4. [PMID: 33223214 DOI: 10.1016/j.jhep.2020.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Razafindrazoto CI, Rasolonjatovo AS, Rabenjanahary TH, Randriamifidy NH, Rakotozafindrabe ALR, Razafimahefa SH, Ramanampamonjy RM. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country? Int J Infect Dis 2021;107:166-9. [PMID: 33895411 DOI: 10.1016/j.ijid.2021.04.061] [Reference Citation Analysis]
186 Matli VVK, Dhahri A, Boda Eswara V, Green LD. Chest Wall Swelling in a Baby Boomer: An Unusual Presentation of Primary Hepatocellular Carcinoma. Cureus 2021;13:e18163. [PMID: 34567914 DOI: 10.7759/cureus.18163] [Reference Citation Analysis]
187 Ha Y, Mohamed Ali MA, Petersen MM, Harmsen WS, Therneau TM, Lee HC, Ryoo BY, Bampoh S, Valles KA, Mady M, Missula VR, Prasai K, Roberts LR, Kim KM. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int 2020;14:776-87. [PMID: 32740886 DOI: 10.1007/s12072-020-10076-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
188 Tergast TL, Kordecki N, Ohlendorf V, Beier C, Sandmann L, Wedemeyer H, Cornberg M, Maasoumy B. [Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure]. Z Gastroenterol 2021. [PMID: 34666403 DOI: 10.1055/a-1649-8931] [Reference Citation Analysis]
189 Berkan-Kawińska A, Piekarska A, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Berak H, Horban A, Zarębska-Michaluk D, Pabjan P, Buczyńska I, Pazgan-Simon M, Dybowska D, Halota W, Pawłowska M, Klapaczyński J, Mazur W, Czauż-Andrzejuk A, Socha Ł, Laurans Ł, Garlicki A, Sitko M, Jaroszewicz J, Citko J, Dobracka B, Krygier R, Białkowska-Warzecha J, Tronina O, Belica-Wdowik T, Baka-Ćwierz B, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver Int 2021;41:1789-801. [PMID: 33655628 DOI: 10.1111/liv.14858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Kang Q, Xu J, Luo H, Tan N, Chen H, Cheng R, Pan J, Han Y, Yang Y, Liu D, Xi H, Yu M, Xu X. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J Viral Hepat 2021;28:1284-92. [PMID: 34105867 DOI: 10.1111/jvh.13558] [Reference Citation Analysis]
191 Hsieh YC, Lee KC, Su CW, Lan KH, Huo TI, Wang YJ, Huang HC, Lin HC, Chu CJ, Huang YH, Hou MC. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J Chin Med Assoc 2021;84:472-7. [PMID: 33742989 DOI: 10.1097/JCMA.0000000000000517] [Reference Citation Analysis]
192 Li J, Wu DB, Jiang W, Chen XB, Xiao GB, Wang YH, Wang ML, Tao YC, Chen EQ. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Medicine (Baltimore) 2020;99:e22726. [PMID: 33120769 DOI: 10.1097/MD.0000000000022726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol 2021;6:391-400. [PMID: 33857445 DOI: 10.1016/S2468-1253(20)30365-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Homolak J, Tomljanović D, Milošević M, Vražić D, Živković M, Budimir I, Pezo Nikolić B, Muslim A, Ljubičić N, Nikolić M. A CROSS-SECTIONAL STUDY OF HEPATITIS B AND HEPATITIS C KNOWLEDGE AMONG DENTAL MEDICINE STUDENTS AT THE UNIVERSITY OF ZAGREB. Acta Clin Croat 2021;60:216-30. [PMID: 34744271 DOI: 10.20471/acc.2021.60.02.07] [Reference Citation Analysis]
195 Tovoli F, Guerra P, Iavarone M, Veronese L, Renzulli M, De Lorenzo S, Benevento F, Brandi G, Stefanini F, Piscaglia F. Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer 2020;9:744-55. [PMID: 33442543 DOI: 10.1159/000509059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
196 Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW. Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study. J Korean Med Sci 2021;36:e142. [PMID: 34060258 DOI: 10.3346/jkms.2021.36.e142] [Reference Citation Analysis]
197 Choi S, Healy S, Shapoval L, Forthal S, Neighbors CJ. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings. Subst Use Misuse 2021;56:258-63. [PMID: 33345680 DOI: 10.1080/10826084.2020.1858106] [Reference Citation Analysis]
198 Pinon M, Giugliano L, Nicastro E, Kakaa O, Coscia A, Carbonara C, D'Antiga L, Calvo PL. Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy. Vaccines (Basel) 2021;9:801. [PMID: 34358216 DOI: 10.3390/vaccines9070801] [Reference Citation Analysis]
199 Pan S, Feng K, Huang P, Zeng Y, Ke L, Yang X, Liu J, Lin C. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Medicine (Baltimore) 2021;100:e26312. [PMID: 34128871 DOI: 10.1097/MD.0000000000026312] [Reference Citation Analysis]